Media Coverage

“The success of a medtech start-up is defined by the global impact of its products. For us, our solutions are being used by pharmaceuticals [in US clinical trials],” says Gideon Ho, CEO of HistoIndex.

HistoIndex is partnering with the University of Malaya and Pathomics Health to roll out an integrative diagnostics platform for the holistic analysis of patient tumor biopsies.

A feature story on more on the world’s first stain-free and multiphoton digital pathology system by Histoindex Pte Ltd and its commitment in combating nonalcoholic steatohepatitis, or NASH.

The Straits Times sat down with our CEO, Dr Gideon Ho, to find out how Histoindex Pte Ltd’s Genesis®200 system is breaking new grounds in developing drugs for liver conditions, particularly non-alcoholic steatohepatitis (NASH).

A winning scientific image, using Histoindex’s Genesis®200 & combined with immunofluorescent staining, is published in the Straits Times today, in Beautiful Science.

“We wanted to create a new standard for how things could be done more objectively and accurately. That’s fundamental to our mission at HistoIndex. At the end of the day, you want a better way to diagnose patients so that they can be treated more optimally, and in doing so, they can live longer and have a better quality of life.”

Zicom Group and Singapore Government agency SPRING Singapore will jointly make their first investment of S$2 million (A$1.9 million) into growth phase medtech start-up Histoindex Pte Ltd.

HistoIndex sets new standards in fibrosis diagnosis and is recognised as an industry-leading emerging company in 2012!